Amsterdam, Sept. 28, 2015 – Holaira, Inc., a developer of medical devices to treat obstructive lung diseases,announced it will host a mini-symposium on Targeted Lung Denervation* (TLD) in patients with moderate to severe COPD, at the European Respiratory Society International Congress, Sept. 28. The program will be co-chaired by Professors Felix Herth, M.D., Ph.D., FCCP, Chairman, Division of Pulmonology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, and Alvar Agustí, M.D., Ph.D., Director of the Thorax Institute at Hospital Clinic in Barcelona. Four scientific experts will present their findings on topics including: Cholinergic Pathways and the Need for New Therapies in COPD; Mechanism of Action and the Holaira™ Lung Denervation System; Long-term Safety and Efficacy of TLD in 37 COPD Patients, and Early Experience from the AIRFLOW-1 Clinical Study.
3750 Annapolis Lane North
Minneapolis, MN 55447
© 2018 Nuvaira Inc. All rights reserved.